Cipla Ltd. — Regulatory Filings 2020

Dec 16, 2020

16[th] December 2020

(1) BSE Ltd (2) National Stock Exchange of India Ltd Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai - 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: 500087 Scrip Code: CIPLA EQ

• (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Press Release - Cipla Launches ‘CIPtest’ Rapid Antigen Detection Test for COVID-19 Diagnosis

Dear Sir / Madam,

Please find enclosed press release dated 16[th] December 2020 for the captioned subject.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking you,

Yours faithfully, For Cipla Limited

Digitally signed by RAJENDRA CHOPRA DN: c=IN, o=Personal, RAJENDRA 2.5.4.20=4987ad48c3965cfde78c8ea69e6f40ac91535876f12ba1fa5ba45cc5cc8db6cb , postalCode=122001, st=HARYANA, serialNumber=0be85c0408d0e3afd663669 CHOPRA f5314248a72fdcdf34d01d48d472d7cf9262696f6, cn=RAJENDRA CHOPRA Date: 2020.12.16 07:52:43 +05'30'

Rajendra Chopra Company Secretary

Encl.as above

Prepared by: Juzer Masta

Press Release

==> picture [90 x 49] intentionally omitted <==

Cipla Launches ‘CIPtest’ Rapid Antigen Detection Test for

COVID-19 Diagnosis

Mumbai, India; December 16, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced its partnership with the Premier Medical Corporation Private Limited for commercialisation of the rapid antigen test kits for COVID-19 in India. The company will commence supply from this week.

This is Cipla’s second launch in the diagnostics space after Elifast: SARS CoV-2 IgG ELISA Test Kit. In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Private Limited.

The test is a rapid point-of-care nasopharyngeal swab test that directly detects the presence or absence of coronavirus antigen in the patient’s body, generating results within 15-20 minutes. Only authorised labs are permitted by ICMR to conduct the rapid antigen testing. The test will be marketed under the brand name ‘CIPtest’.

CIPtest is a reliable high-performing kit that has been validated and approved by ICMR. It is found to have specificity and sensitivity of 98.09% and upto 75 % respectively. The test is not only rapid with a quick turn-around time, but also enables easy interpretation of results without the need of any additional instrument. Cipla’s expansive distribution network will help in ensuring supply of kits across the country.

About Cipla :

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3[rd] largest in pharma in India (IQVIA MAT September’ 20), 3[rd] largest in the pharma private market in South Africa (IQVIA MAT September’20), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to

==> picture [584 x 65] intentionally omitted <==

==> picture [90 x 49] intentionally omitted <==

healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

For queries, please contact :

Corporate Communications Investor Relations Heena Kanal Naveen Bansal E-Mail: CorpComm@cipla.com E-Mail: Investor.Relations@cipla.com

==> picture [584 x 65] intentionally omitted <==